Janus Henderson Group’s Inovio Pharmaceuticals INO Stock Holding History

Janus Henderson Group’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.77M	Hold	3,308,406	–	–	﹤0.01%	917
2025 Q4	$5.77M	Buy	3,308,406 +42,146	+1%	+$92.8K	﹤0.01%	887
2025 Q3	$7.63M	Buy	+3,266,260	New	+$6.25M	﹤0.01%	807
2023 Q2	–	Sell	-8,510	Closed	-$83.7K	–	2638
2023 Q1	$83.7K	Buy	8,510 +5,000	+142%	+$85.2K	﹤0.01%	2631
2022 Q4	$65.5K	Hold	3,510	–	–	﹤0.01%	2397
2022 Q3	$72K	Buy	3,510 +10	+0.3%	+$256	﹤0.01%	2094
2022 Q2	$73K	Hold	3,500	–	–	﹤0.01%	2516
2022 Q1	$151K	Buy	+3,500	New	+$158K	﹤0.01%	2497

Other funds holding INO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group's INO Position: Q1 2026 in Review

Janus Henderson Group held its Inovio Pharmaceuticals (INO) position steady in Q1 2026 at 3,308,406 shares worth $5.77M. The position accounts for ﹤0.01% of the portfolio, ranked #917.

Janus Henderson Group first reported a position in INO in Q1 2022 and has held it in 8 quarters since. The position peaked at $7.63M in Q3 2025. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

Janus Henderson Group held 3,308,406 shares of Inovio Pharmaceuticals worth $5.77M as of Q1 2026.
Janus Henderson Group left its Inovio Pharmaceuticals share count unchanged in Q1 2026.
Inovio Pharmaceuticals made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #917 holding.
Janus Henderson Group first reported a position in Inovio Pharmaceuticals in Q1 2022 and has held it in 8 quarters since.
Janus Henderson Group's Inovio Pharmaceuticals position peaked at $7.63M in Q3 2025.
100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.